Widefield color fundus images of a patient with proliferative diabetic retinopathy demonstrate widespread panretinal photocoagulation scars and a visible intravitreal, whitish dexamethasone implant within the vitreous cavity of both eyes.
Dexamethasone intravitreal implant is a sustained-release corticosteroid delivery system indicated for the treatment of macular edema secondary to retinal vein occlusion, non-infectious posterior uveitis, and diabetic macular edema. The biodegradable implant releases dexamethasone gradually over several months, exerting potent anti-inflammatory and anti-edematous effects while minimizing systemic exposure. Its efficacy in reducing central retinal thickness and improving visual acuity has been well-documented in multiple randomized clinical trials.